A 2018 report by PrEP Watch revealed 26,000 Kenyan users of pre-exposure prophylaxis (PrEP) against a target of 37,000, underscoring ongoing challenges in expanding access to the HIV prevention drug. This context accompanies new findings demonstrating that combining PrEP with antiretroviral therapy (ART) eliminates transmission risks during pregnancy for HIV-discordant couples.
Research led by Jomo Kenyatta University of Agriculture and Technology's Kenneth Ngure tracked 74 couples, with 40 pregnancies resulting in HIV-negative births. The study involved administering ART to HIV-positive partners and PrEP to negative partners, paired with timed unprotected intercourse during fertile periods. None of the 40 pregnancies resulted in transmission, according to the team's analysis.
Ngure emphasized that 200,000 HIV-discordant couples in Kenya face challenges balancing reproductive desires with transmission risks. He noted cultural pressures driving natural conception attempts despite infection risks, while highlighting the study's implications for scaling safe conception methods. The research team observed that couples preferred combining PrEP, ART, and timed intercourse over artificial insemination due to misconceptions about alternative methods.
PrEP, primarily using Truvada—a single pill containing tenofovir and emtricitabine—has shown effectiveness in preventing HIV transmission. ART suppresses the virus in infected individuals and prevents onward transmission. Ngure stated the findings could inform broader implementation of these protocols to address Kenya's significant population of HIV-discordant couples.
